ACRHD

AcronymDefinition
ACRHDAdvisory Committee for Reproductive Health Drugs
References in periodicals archive ?
(Thousand Oaks, CA) will summarize data from the submitted Biologic License Applications (BLAs) for denosumab for the prevention and treatment of postmenopausal osteoporosis and the prevention and treatment of bone loss in breast and prostate cancer patients undergoing hormone ablation at a meeting with the United States Food and Drug Administration's Advisory Committee for Reproductive Health Drugs (ACRHD).
The ACRHD will discuss the use of denosumab in each of four indications outlined in the BLAs: